# Evaluation of Skin Health and QoL in Pts Receiving Anti-PD1/PDL1/CTLA4 or CDK Inhibitors.

> **NCT05878964** · — · RECRUITING · sponsor: **Fondazione Policlinico Universitario Agostino Gemelli IRCCS** · enrollment: 420 (estimated)

## Conditions studied

- Lung Cancer
- Breast Cancer
- Kidney Cancer
- Bladder Cancer
- Gastric Cancer
- Skin Cancer
- Melanoma
- Head Neck Cancer

## Interventions

- **OTHER:** EQ-5D-5L questionnaire
- **OTHER:** FACT-G (Functional Assessment of Cancer Therapy - General)
- **OTHER:** FACT-EGFRI-18 (Functional Assessment of Cancer Therapy - Epidermal Growth Factor Inhibitors 18 Item)

## Key facts

- **NCT ID:** NCT05878964
- **Lead sponsor:** Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-22
- **Primary completion:** 2025-07-22
- **Final completion:** 2025-09-22
- **Target enrollment:** 420 (ESTIMATED)
- **Last updated:** 2024-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05878964

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05878964, "Evaluation of Skin Health and QoL in Pts Receiving Anti-PD1/PDL1/CTLA4 or CDK Inhibitors.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05878964. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*